Abstract:Background Targeted splice modulation of pre-mRNA transcripts by antisense oligonucleotides (AOs) can correct the function of aberrant disease-related genes. Duchenne muscular dystrophy (DMD) arises as a result of mutations that interrupt the open-reading frame in the DMD gene encoding dystrophin such that dystrophin protein is absent, leading to fatal muscle degeneration. AOs have been shown to correct this dystrophin defect via exon skipping to yield functional dystrophin protein in animal models of DMD and also in DMD patients via intramuscular administration. To advance this therapeutic method requires increased exon skipping efficiency via an optimized AO sequence, backbone chemistry and additional modifications, and the improvement of methods for evaluating AO efficacy.Methods In the present study, we establish the conditions for rapid in vitro AO screening in H2K muscle cells, in which we evaluate the exon skipping properties of a number of known and novel AO chemistries [2'-O-methyl, peptide nucleic acid, phosphorodiamidate morpholino (PMO)] and their peptide-conjugated derivatives and correlate their in vitro and in vivo exon skipping activities.Results The present study demonstrates that using AO concentrations of 300 nm with analysis at a single time-point of 24 h post-transfection allowed the effective in vitro screening of AO compounds to yield data predictive of in vivo exon skipping efficacy. Peptide-conjugated PMO AOs provided the highest in vitro activity. We also show for the first time that the feasibility of rapid AO screening extends to primary cardiomyocytes.Conclusions In vitro screening of different AOs within the same chemical class is a reliable method for predicting the in vivo exon skipping efficiency of AOs for DMD. Copyright (C) 2010 John Wiley & Sons, Ltd.

Self‐Assembled Antibody‐Oligonucleotide Conjugates for Targeted Delivery of Complementary Antisense Oligonucleotides

Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)

Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development

Systemic antibody-oligonucleotide delivery to the central nervous system ameliorates mouse models of spinal muscular atrophy

Synthesis and Exon-Skipping Properties of a 3′-Ursodeoxycholic Acid-Conjugated Oligonucleotide Targeting DMD Pre-mRNA: Pre-Synthetic versus Post-Synthetic Approach

Modified ASO Conjugates Encapsulated with Cytidinyl/cationic Lipids Exhibit More Potent and Longer-Lasting Anti-Hcc Effects

A Modular Albumin-Oligonucleotide Biomolecular Assembly for Delivery of Antisense Therapeutics

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates Library

Effective Exon Skipping and Dystrophin Restoration by 2 '-O-methoxyethyl Antisense Oligonucleotide in Dystrophin-Deficient Mice

Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs

I-Motif-Based in Situ Bipedal Hybridization Chain Reaction for Specific Activatable Imaging and Enhanced Delivery of Antisense Oligonucleotides

Enhanced antisense oligonucleotide delivery using cationic liposomes incorporating fatty acid-modified polyethylenimine.

Going nuclear: Improved antisense oligonucleotide activity through conjugation with a nuclear importer

Cancer-cell-membrane-camouflaged Supramolecular Self-Assembly of Antisense Oligonucleotide and Chemodrug for Targeted Combination Therapy

"Intercellular Mass Transport" Mimic Enables ASO Entry Completely into the Cell Nucleus for Enhanced Ischemia Therapy

In Vitro Evaluation of Novel Antisense Oligonucleotides is Predictive of in Vivo Exon Skipping Activity for Duchenne Muscular Dystrophy

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy

Peptide Conjugates of a 2'- O-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes

A Polyethylenimine-Linoleic Acid Conjugate for Antisense Oligonucleotide Delivery

SCAD Delivery Platform: A Novel Approach for Efficient CNS and Extrahepatic Oligonucleotide Therapeutics